Payment overview · 2025
General Payments
$169.36
9 reported records · 6 companies
Healthcare provider profile · identity verified
William E Sowers, MD
Allopathic & Osteopathic Physicians|Family Medicine · MUNCIE, IN · NPI 1841378833
Verified facts
What the public records show
CMS Open Payments records show William E Sowers, MD received $169.36 in general payments during 2025 across 9 reported records.
Novo Nordisk Inc accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 59 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 93 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 140 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $44.87 | 26.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $44.78 | 26.4% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $27.07 | 16.0% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.85 | 11.1% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $17.57 | 10.4% | 1 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$16.22 | 9.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $150.51 | 8 |
| Education | $18.85 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.78 | 2 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $27.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| PROQUAD Normalized: proquad |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VAXELIS Normalized: vaxelis |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VAXNEUVANCE Normalized: vaxneuvance |
Biological | Merck Sharp & Dohme LLC | $17.57 | 1 | 2025 |
Source payment records
|
|||||
| VENASEAL Normalized: venaseal |
Device | Medtronic, Inc. | $16.22 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.63 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 140 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 59 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
59 | 15 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
93 | 27 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
140 | 32 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 917 | 269 |
| Amlodipine Besylate | Amlodipine Besylate | 594 | 151 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 548 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 511 | 137 |
| Gabapentin | Gabapentin | 419 | 103 |
| Lisinopril | Lisinopril | 377 | 114 |
| Metoprolol Succinate | Metoprolol Succinate | 345 | 98 |
| Omeprazole | Omeprazole | 341 | 100 |
| Pantoprazole Sodium | Pantoprazole Sodium | 337 | 98 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 282 | 39 |
| Alprazolam | Alprazolam | 273 | 34 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 270 | 83 |
| Carvedilol | Carvedilol | 267 | 77 |
| Metformin Hcl | Metformin Hcl | 261 | 83 |
| Losartan Potassium | Losartan Potassium | 248 | 71 |
| Hydrochlorothiazide | Hydrochlorothiazide | 244 | 70 |
| Escitalopram Oxalate | Escitalopram Oxalate | 233 | 59 |
| Furosemide | Furosemide | 230 | 59 |
| Potassium Chloride | Potassium Chloride | 229 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 216 | 61 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 176 | 67 |
| Duloxetine Hcl | Duloxetine Hcl | 164 | 46 |
| Pravastatin Sodium | Pravastatin Sodium | 163 | 42 |
| Clopidogrel | Clopidogrel Bisulfate | 145 | 43 |
| Eliquis | Apixaban | 140 | 32 |
| Allopurinol | Allopurinol | 136 | 43 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 35 |
| Montelukast Sodium | Montelukast Sodium | 131 | 43 |
| Metoprolol Tartrate | Metoprolol Tartrate | 128 | 39 |
| Synthroid | Levothyroxine Sodium | 127 | 33 |
| Trazodone Hcl | Trazodone Hcl | 125 | 31 |
| Tramadol Hcl | Tramadol Hcl | 123 | 21 |
| Meloxicam | Meloxicam | 121 | 40 |
| Simvastatin | Simvastatin | 117 | 31 |
| Valsartan | Valsartan | 111 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 105 | 31 |
| Alendronate Sodium | Alendronate Sodium | 104 | 31 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 96 | 76 |
| Ozempic | Semaglutide | 93 | 27 |
| Metformin Hcl Er | Metformin Hcl | 92 | 23 |
| Zolpidem Tartrate | Zolpidem Tartrate | 89 | 20 |
| Clonazepam | Clonazepam | 88 | 13 |
| Pregabalin | Pregabalin | 88 | 17 |
| Lorazepam | Lorazepam | 87 | 18 |
| Sertraline Hcl | Sertraline Hcl | 87 | 27 |
| Buspirone Hcl | Buspirone Hcl | 85 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 85 | 71 |
| Torsemide | Torsemide | 85 | 32 |
| Farxiga | Dapagliflozin Propanediol | 84 | 20 |
| Topiramate | Topiramate | 83 | 22 |
| Mirtazapine | Mirtazapine | 80 | 17 |
| Mounjaro | Tirzepatide | 79 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 78 | 22 |
| Bupropion Xl | Bupropion Hcl | 74 | 20 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 74 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 71 | 20 |
| Ezetimibe | Ezetimibe | 70 | 26 |
| Benazepril Hcl | Benazepril Hcl | 69 | 19 |
| Fluoxetine Hcl | Fluoxetine Hcl | 65 | 23 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 61 | 14 |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 59 | 19 |
| Diazepam | Diazepam | 59 | suppressed |
| Jardiance | Empagliflozin | 59 | 15 |
| Tizanidine Hcl | Tizanidine Hcl | 58 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 57 | 20 |
| Methylprednisolone | Methylprednisolone | 53 | 47 |
| Finasteride | Finasteride | 51 | 16 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 51 | 46 |
| Ropinirole Hcl | Ropinirole Hcl | 49 | 17 |
| Spironolactone | Spironolactone | 48 | 14 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 47 | 14 |
| Januvia | Sitagliptin Phosphate | 46 | 11 |
| Ibuprofen | Ibuprofen | 45 | 15 |
| Promethazine Hcl | Promethazine Hcl | 45 | 11 |
| Morphine Sulfate Er | Morphine Sulfate | 44 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 43 | 14 |
| Glimepiride | Glimepiride | 42 | 11 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 42 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 41 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 40 | 11 |
| Ondansetron Hcl | Ondansetron Hcl | 40 | 16 |
| Trulicity | Dulaglutide | 39 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 39 | 13 |
| Fentanyl | Fentanyl | 37 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 36 | 31 |
| Prednisone | Prednisone | 36 | 23 |
| Risedronate Sodium | Risedronate Sodium | 36 | suppressed |
| Acyclovir | Acyclovir | 35 | 12 |
| Glipizide Er | Glipizide | 35 | suppressed |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Atenolol | Atenolol | 34 | suppressed |
| Azithromycin | Azithromycin | 34 | 26 |
| Clonidine Hcl | Clonidine Hcl | 34 | suppressed |
| Famotidine | Famotidine | 34 | suppressed |
| Klor-Con M20 | Potassium Chloride | 33 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 33 | 11 |
| Raloxifene Hcl | Raloxifene Hcl | 32 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 31 | suppressed |
| Linzess | Linaclotide | 31 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | suppressed |
| Aripiprazole | Aripiprazole | 30 | 11 |
| Breo Ellipta | Fluticasone/Vilanterol | 30 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 30 | suppressed |
| Methocarbamol | Methocarbamol | 30 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 29 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 28 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 27 | 23 |
| Entresto | Sacubitril/Valsartan | 27 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 27 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 26 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 26 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 26 | suppressed |
| Verapamil Er | Verapamil Hcl | 26 | suppressed |
| Celecoxib | Celecoxib | 24 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Sucralfate | Sucralfate | 23 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 23 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 22 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 21 | suppressed |
| Estradiol | Estradiol | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 20 | suppressed |
| Carisoprodol | Carisoprodol | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 20 | suppressed |
| Memantine Hcl | Memantine Hcl | 20 | suppressed |
| Trimethoprim | Trimethoprim | 20 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 19 | 18 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 19 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 19 | suppressed |
| Hydrocortisone | Hydrocortisone | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 18 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Lansoprazole | Lansoprazole | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | 17 |
| Meclizine Hcl | Meclizine Hcl | 17 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 17 | suppressed |
| Vascepa | Icosapent Ethyl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 16 | suppressed |
| Febuxostat | Febuxostat | 16 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 16 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 16 | suppressed |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 16 | suppressed |
| Ondansetron Odt | Ondansetron | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 15 | 15 |
| Chlorthalidone | Chlorthalidone | 15 | suppressed |
| Lamotrigine | Lamotrigine | 15 | suppressed |
| Lovastatin | Lovastatin | 15 | suppressed |
| Lubiprostone | Lubiprostone | 15 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 15 | suppressed |
| Vilazodone Hcl | Vilazodone Hcl | 15 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 14 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 14 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 13 | suppressed |
| Bydureon Bcise | Exenatide Microspheres | 13 | suppressed |
| Cephalexin | Cephalexin | 13 | suppressed |
| Diclofenac Sodium Er | Diclofenac Sodium | 13 | suppressed |
| Digoxin | Digoxin | 13 | suppressed |
| Nystatin | Nystatin | 13 | suppressed |
| Risperidone | Risperidone | 13 | suppressed |
| Armodafinil | Armodafinil | 12 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 12 | suppressed |
| Felodipine Er | Felodipine | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 12 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 12 | suppressed |
| Clotrimazole | Clotrimazole | 11 | suppressed |
| Diclofenac Sodium-Misoprostol | Diclofenac Sodium/Misoprostol | 11 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $169.36 · 9 records | Novo Nordisk Inc | CAPVAXIVE, ELIQUIS, GARDASIL 9, JARDIANCE, NURTEC ODT, PROQUAD, VAXELIS, VAXNEUVANCE, VENASEAL, WATCHMAN FLX, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error